News Image

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Provided By GlobeNewswire

Last update: Mar 4, 2025

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023.

Read more at globenewswire.com

DAXOR CORP

NASDAQ:DXR (10/17/2025, 8:07:29 PM)

12.9456

-0.05 (-0.42%)



Find more stocks in the Stock Screener

Follow ChartMill for more